Uber Surpasses Profit Expectations in 14th Yearby Mark Eisenberg 12.02.2024Uber reports first annual profit in 14 years, beating analyst estimates. Gross bookings and total trips taken showed significant growth. ...
GRANOLAS Stocks Outperform Tech Titansby Mark Eisenberg 12.02.2024European blue-chip stocks known as the GRANOLAS group have outperformed the Magnificent 7 in the European market, accounting for 60% ...
Bank of America Analysts: Small-Caps the Market’s Hidden Gemby Mark Eisenberg 12.02.2024Despite the market rally, small-cap stocks have become cheaper, making them an attractive option for investors. Bank of America analysts ...
Shell’s Bonny Terminal Fuels Nigeria’s Refinery Revival.by Mark Eisenberg 12.02.2024Shell Nigeria has resumed oil supply to the Port Harcourt Refinery after a five-year outage, reducing the country's dependence on ...
Bristol Myers Bags RayzeBio in $4.1B Cancer Fight Pactby Mark Eisenberg 12.02.2024Pharma giant Bristol Myers Squibb acquires RayzeBio for $4.1 billion, expanding its presence in the oncology sector and strengthening its ...
Apple’s AI-Driven iPhone Boost Spurs Stock Growthby Lilu Anderson 12.02.2024Analysts predict AI-integrated iPhones could boost Apple's stock and sales, potentially leading to more device replacements and revenue opportunities.
Hasbro Q4 Earnings: Recovery or Stagnation Ahead?by Mark Eisenberg 12.02.2024Hasbro is set to release its Q4 results, with a predicted profit increase but a 20% decline in revenue. Analysts ...
Organigram Makes Groundbreaking Entry into German Cannabis Marketby John Darbie 12.02.2024Canadian cannabis producer Organigram Holdings Inc. has made its first shipment of bulk dried flower to Sanity Group, entering the ...
Loop Capital Downgrades FMC Corp.: Sell Now?by Mark Eisenberg 12.02.2024Loop Capital downgrades FMC Corp. to Hold and lowers price target due to inventory challenges in critical markets. Concerns over ...
Oppenheimer Trims Gilead Sciences Price Targetby Mark Eisenberg 12.02.2024Oppenheimer lowers price target on Gilead Sciences after Q4 earnings report and challenges in drug pipeline. Optimistic about prospects for ...